The multifaceted role of NRF2 in cancer progression and cancer stem cells maintenance

被引:33
作者
Choi, Bo-Hyun [1 ]
Kim, Jin Myung [2 ]
Kwak, Mi-Kyoung [2 ,3 ]
机构
[1] Daegu Catholic Univ, Sch Med, Dept Pharmacol, Daegu 42472, South Korea
[2] Catholic Univ Korea, Dept Pharm, Grad Sch, Gyeonggi Do 14662, South Korea
[3] Catholic Univ Korea, Dept Pharm, Grad Sch, 43 Jibong Ro, Bucheon 14662, Gyeonggi Do, South Korea
基金
新加坡国家研究基金会;
关键词
NRF2; KEAP1; Cancer; Cancer stem cell; Therapy resistance; TRANSCRIPTION FACTOR NRF2; HEME OXYGENASE-1 EXPRESSION; LUNG-CANCER; BREAST-CANCER; OXIDATIVE STRESS; SIDE POPULATION; SELF-RENEWAL; HEPATOCELLULAR-CARCINOMA; ACTIVATION PROMOTES; SIGNALING PATHWAY;
D O I
10.1007/s12272-021-01316-8
中图分类号
R914 [药物化学];
学科分类号
100705 [微生物与生化药学];
摘要
The transcription factor nuclear factor erythroid 2-like 2 (NEF2L2; NRF2) plays crucial roles in the defense system against electrophilic or oxidative stress by upregulating an array of genes encoding antioxidant proteins, electrophile/reactive oxygen species (ROS) detoxifying enzymes, and drug efflux transporters. In contrast to the protective roles in normal cells, the multifaceted role of NRF2 in tumor growth and progression, resistance to therapy and intratumoral stress, and metabolic adaptation is rapidly expanding, and the complex association of NRF2 with cancer signaling networks is being unveiled. In particular, the implication of NRF2 signaling in cancer stem cells (CSCs), a small population of tumor cells responsible for therapy resistance and tumor relapse, is emerging. Here, we described the dark side of NRF2 signaling in cancers discovered so far. A particular focus was put on the role of NRF2 in CSCs maintenance and therapy resistance, showing that low ROS levels and refractory drug response of CSCs are mediated by the activation of NRF2 signaling. A better understanding of the roles of the NRF2 pathway in CSCs will allow us to develop a novel therapeutic approach to control tumor relapse after therapy.
引用
收藏
页码:263 / 280
页数:18
相关论文
共 189 条
[1]
Drug-induced Senescence Generates Chemoresistant Stemlike Cells with Low Reactive Oxygen Species [J].
Achuthan, Santhi ;
Santhoshkumar, Thankayyan R. ;
Prabhakar, Jem ;
Nair, S. Asha ;
Pillai, M. Radhakrishna .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (43) :37813-37829
[2]
Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles [J].
Agyeman, Abena S. ;
Chaerkady, Raghothama ;
Shaw, Patrick G. ;
Davidson, Nancy E. ;
Visvanathan, Kala ;
Pandey, Akhilesh ;
Kensler, Thomas W. .
BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (01) :175-187
[3]
Guggulsterone induces heme oxygenase-1 expression through activation of Nrf2 in human mammary epithelial cells: PTEN as a putative target [J].
Almazari, Inas ;
Park, Jong-Min ;
Park, Sin-Aye ;
Suh, Jin-Young ;
Na, Hye-Kyung ;
Cha, Young-Nam ;
Surh, Young-Joon .
CARCINOGENESIS, 2012, 33 (02) :368-376
[4]
The Crosstalk between Nrf2 and TGF-β1 in the Epithelial-Mesenchymal Transition of Pancreatic Duct Epithelial Cells [J].
Arfmann-Knuebel, Sarah ;
Struck, Birte ;
Genrich, Geeske ;
Helm, Ole ;
Sipos, Bence ;
Sebens, Susanne ;
Schaefer, Heiner .
PLOS ONE, 2015, 10 (07)
[5]
Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity [J].
Arlt, A. ;
Sebens, S. ;
Krebs, S. ;
Geismann, C. ;
Grossmann, M. ;
Kruse, M-L ;
Schreiber, S. ;
Schaefer, H. .
ONCOGENE, 2013, 32 (40) :4825-4835
[6]
BAINES P, 1983, EXP HEMATOL, V11, P701
[7]
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response [J].
Bao, Shideng ;
Wu, Qiulian ;
McLendon, Roger E. ;
Hao, Yueling ;
Shi, Qing ;
Hjelmeland, Anita B. ;
Dewhirst, Mark W. ;
Bigner, Darell D. ;
Rich, Jeremy N. .
NATURE, 2006, 444 (7120) :756-760
[8]
Cancer stem cells revisited [J].
Batlle, Eduard ;
Clevers, Hans .
NATURE MEDICINE, 2017, 23 (10) :1124-1134
[9]
Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment [J].
Best, Sarah A. ;
De Souza, David P. ;
Kersbergen, Ariena ;
Policheni, Antonia N. ;
Dayalan, Saravanan ;
Tull, Dedreia ;
Rathi, Vivek ;
Gray, Daniel H. ;
Ritchie, Matthew E. ;
McConville, Malcolm J. ;
Sutherland, Kate D. .
CELL METABOLISM, 2018, 27 (04) :935-+
[10]
Brusatol, an NRF2 inhibitor for future cancer therapeutic [J].
Cai, Sabrina J. ;
Liu, Yang ;
Han, Sue ;
Yang, Chunzhang .
CELL AND BIOSCIENCE, 2019, 9 (1)